In this issue:
The global burden of AD
Lack of clinical trial data in older adults for systemic AD medications
Postmarketing study finds no increased risk of keratinocyte carcinoma with TCI use
Patients with severe AD have an increased risk of systemic infections
Dupilumab associated with higher risk of conjunctivitis
Conjunctivitis in dupilumab clinical trials for adolescents
LIBERTY AD PRE-SCHOOL finds dupilumab efficacious and safe in paediatric patients
Pooled analysis finds baricitinib safe in adult patients
BREEZE-AD7 confirms efficacy of oral 4 mg baricitinib with background TCS use
Tapinarof cream may provide a novel therapeutic option for AD
Please login below to download this issue (PDF)